Summary
Global Markets Direct’s, ‘Traveler's Diarrhea - Pipeline Review, H1 2016’, provides an overview of the Traveler's Diarrhea pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Traveler's Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traveler's Diarrhea and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Traveler's Diarrhea
- The report reviews pipeline therapeutics for Traveler's Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Traveler's Diarrhea therapeutics and enlists all their major and minor projects
- The report assesses Traveler's Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Traveler's Diarrhea
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Traveler's Diarrhea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Traveler's Diarrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Chiesi Farmaceutici SpA
Cosmo Pharmaceuticals S.p.A
GlaxoSmithKline Plc
Nippon Shinyaku Co., Ltd.
Prokarium Limited
Scandinavian Biopharma Holding AB
Sigmoid Pharma Limited
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Traveler's Diarrhea Overview 7
Therapeutics Development 8
Pipeline Products for Traveler's Diarrhea - Overview 8
Pipeline Products for Traveler's Diarrhea - Comparative Analysis 9
Traveler's Diarrhea - Therapeutics under Development by Companies 10
Traveler's Diarrhea - Therapeutics under Investigation by Universities/Institutes 11
Traveler's Diarrhea - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Traveler's Diarrhea - Products under Development by Companies 15
Traveler's Diarrhea - Products under Investigation by Universities/Institutes 16
Traveler's Diarrhea - Companies Involved in Therapeutics Development 17
Chiesi Farmaceutici SpA 17
Cosmo Pharmaceuticals S.p.A 18
GlaxoSmithKline Plc 19
Nippon Shinyaku Co., Ltd. 20
Prokarium Limited 21
Scandinavian Biopharma Holding AB 22
Sigmoid Pharma Limited 23
Traveler's Diarrhea - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
ACE-527 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ACE-920 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Etvax - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GVXNSD-133 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Helicobacter pylori [strain Hel-305] (multivalent) vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
IMSUTMR-1501 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
prulifloxacin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
rifamycin CR - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Typhetec - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Vaccine for Traveler's Diarrhea - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Traveler's Diarrhea - Recent Pipeline Updates 48
Traveler's Diarrhea - Discontinued Products 51
Traveler's Diarrhea - Product Development Milestones 52
Featured News & Press Releases 52
Oct 04, 2013: Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers’ Diarrhea 52
Sep 11, 2012: Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers' Diarrhea 53
Aug 17, 2011: TD Vaccines To Present ACE527 Phase II Data At Sachs 11th Annual Biotech In Europe 54
Sep 14, 2009: Data From Optimers Second Phase III Study of Prulifloxacin Presented At Annual Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) 54
Sep 02, 2009: Optimer Pharmaceuticals Announces Presentations Of Additional Phase III Prulifloxacin Data At Upcoming ICAAC Annual Meeting 55
Feb 26, 2009: Optimer Pharmaceuticals Announces Publication In Peer-Reviewed Journal About Prulifloxacins Antibacterial Activity Against Infectious Diarrhea Producing Bacteria 56
Feb 24, 2009: Optimer Pharmaceuticals Announces Positive Results From Second Phase III Study Of Prulifloxacin For Infectious Diarrhea In Travelers 56
Oct 20, 2008: Data from Optimer Pharmaceuticals Prulifloxacin Phase III Trial In Travelers Diarrhea Presented At ICAAC/IDSA Annual Meeting 57
Sep 02, 2008: Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase III Clinical Trial 58
Jul 16, 2008: Optimer Pharmaceuticals Announces Positive Results In Prulifloxacin Phase III Study 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60
List of Tables
Number of Products under Development for Traveler's Diarrhea, H1 2016 8
Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Traveler's Diarrhea - Pipeline by Chiesi Farmaceutici SpA, H1 2016 17
Traveler's Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2016 18
Traveler's Diarrhea - Pipeline by GlaxoSmithKline Plc, H1 2016 19
Traveler's Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 20
Traveler's Diarrhea - Pipeline by Prokarium Limited, H1 2016 21
Traveler's Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2016 22
Traveler's Diarrhea - Pipeline by Sigmoid Pharma Limited, H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Traveler's Diarrhea Therapeutics - Recent Pipeline Updates, H1 2016 48
Traveler's Diarrhea - Discontinued Products, H1 2016 51
List of Figures
Number of Products under Development for Traveler's Diarrhea, H1 2016 8
Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Targets, H1 2016 25
Number of Products by Stage and Targets, H1 2016 25
Number of Products by Mechanism of Actions, H1 2016 27
Number of Products by Stage and Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31
